Effect of paricalcitol and enalapril on renal inflammation/oxidative stress in atherosclerosis

Figure 3 Western blot analysis and densitometry of protein band analysis to paricalcitol and enalapril alone and in combination for 16-wk on renal NADPH oxidase subunit p22phox, manganese-superoxide dismutase and copper/zinc-superoxide dismutase protein expression in ApoE-deficient atherosclerotic mice. A: Western blot analysis of the effect of paricalcitol and enalapril alone and in combination for 16-wk on renal NADPH oxidase subunit p22phox, manganese-superoxide dismutase (Mn-SOD) and copper/zinc-superoxide dismutase (CuZn-SOD) protein expression in ApoE-deficient atherosclerotic mice; B: Densitometry of protein band analysis show that renal NADPH oxidase subunit p22phox and Mn-SOD expression significantly increased (P < 0.001) whereas CuZn-SOD protein expression significantly decreased (P < 0.001) in atherosclerotic mice (n = 3) compared to controls (n = 3). Paricalcitol (n = 3), enalapril (n = 3) and combination of the two (n = 3) significantly (P < 0.02 and P < 0.001) ameliorated the oxidative stress by inhibiting the induction of NADPH oxidase and Mn-SOD expression (38%, 76% and 68%, respectively) and up-regulating the CuZn-SOD protein expression (52%, 342% and 398%, respectively) in atherosclerotic mice. The data represent mean ± SE of three independent Western blot experiments.